MARKET COMPOSITE
GERN - Geron Corp.8:00:00 PM 3/28/2024
Price
$3.30
-0.01 (-0.30%)
Geron Corporation is a biotechnology company located in Menlo Park, California, which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase. Geron, based in Menlo Park, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. The company was incorporated in 1990 and began doing business in 1992. John A. Scarlett was appointed CEO in 2011.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue23K-86%
Operating Income-54.3MM+14%
Operating Expenses54.3MM+14%
Net Income-52MM+16%
R&D32.9MM+12%
G&A21.4MM+17%
Interest Expense2.3MM+12%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.

    FOSTER CITY, Calif., March 19, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. The offering included

    Shares of both Geron (GERN) and Madrigal Pharmaceuticals (MDGL) are soaring after receiving positive news from the Food and Drug Administration. For Geron, an FDA advisory panel backed its blood disorder treatment. For Madrigal, the FDA approved its treatment for a liver disease known as nonalcoholic steatohepatitis, or NASH. Yahoo Finance's Josh Lipton and Julie Hyman discuss the stocks' reaction in the video above. For more expert insight and the latest market action, click here to watch this ...

    [**Adobe (ADBE)**](https://www.wsj.com/market-data/quotes/ADBE): The software company's latest results topped forecasts, but guidance for its current quarter [disappointed investors](https://www.wsj.com/livecoverage/stock-market-today-dow-jones-03-15-2024/card/adobe-reports-solid-earnings-but-stock-sinks-after-outlook-underwhelms-investors-fg7wmoXAIxD5cpqyO7v8).

    Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.

    Geron Corp (NASDAQ:GERN) shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia. What Happened: After the market close on Thursday, Geron announced that ODAC voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusio

    FOSTER CITY, Calif., March 14, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-inte

    Advisers to the U.S. Food and Drug Administration on Thursday voted in favor of Geron's blood disorder drug, stating that, based on late-stage trial data, the benefits outweigh treatment associated risks in patients. The panel, by a wide 12-to-2 margin, backed the benefits of the injectable drug, called imetelstat, stating the associated risks and toxicities of the treatment were manageable. Geron is seeking approval to use imetelstat for treating transfusion-dependent anemia in patients with ...

    Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.

    The U.S. Food and Drug Administration's staff reviewers said on Tuesday they were unclear if Geron's blood disorder drug provided a clear benefit to patients in a late-stage trial and raised multiple safety concerns with the treatment. Shares of the California-based company fell 11.5% following the release of the briefing documents, ahead of a meeting of the FDA's independent advisers scheduled for Thursday. Geron is seeking approval of the injectable drug, called imetelstat, for treating tran...